peter kolchinsky age

Prior to Localytics, Matt served as software engineer at Mathworks. Meredith holds a BS in Biology: Pre-Med from the University of North Carolina at Charlotte. After leaving Schrodinger in 2018, Soumya founded 3-Dimensional Consulting, a boutique Physics Based and Machine-Learning focused computational chemistry consulting firm that provides scientific support for early-stage drug discovery and company formation within various Boston-based venture firms including: Atlas Venture, 3rd Rock, MPM Capital, and RA Capital. Laura works on new company creation and early-stage investments, and serves as a Board Director for Be Biopharma, Expansion Therapeutics, Hemab, and Aliada Therapeutics. May 27, 2022 (This is a long piece; click here to read it in Bionic Reading format, which may for some increase reading speed and comprehension. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. Prior to that, David worked as Director of Operations for Wingspan Investment Management, LP and held operations positions at Brencourt Advisors and Silver Point Capital, LP. Special Projects Operations Manager/Chief of Staff. and Ultragenyx Pharmaceuticals. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. From 2016-2017, Scott served as President of Sojournix, Inc., an asset-focused biopharmaceutical company that he co-founded and served as Board member until 2021. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Prior to KPMG, Ryan worked at Morris and Morris, P.C. Prior to IGEN Cony worked for Corning in the US and in Europe. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Habib Dable is a Venture Partner at RA Ventures (RAVen), focusing on advising and supporting newcos, portfolio companies and executives within RAVen. Peter Kolchinsky (PhD '01) is a co-founder and General Partner of RA Capital Management, which has been investing in healthcare companies since 2002.He is a member of the National Academies Board on Global Science and Technology, authored an e-book titled The Entrepreneur's Guide to a Biotech Startup, and serves as an advisor to startup companies and non-profits. Jaimie's primary responsibilities are to coordinate calendars, events, and company meetings for RA Venture Partners and EIRs. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. Ben has also mapped competitive landscapes with a focus on cardiovascular diseases and regenerative medicine as a member of the Cardio-Renal Team within the TechAtlas division of RA Capital. Joey ONeill is an Investor Services Associate at RA Capital Management. Brigid holds a BS in Chemistry (Hons) from the Commonwealth Honors College at the University of Massachusetts, Amherst (2002) and a PhD in Materials Science and Engineering from Johns Hopkins University (2009). MarketScreener: Created by Investors for Investors! Megans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Lucas Guevara is a Compliance Counsel at RA Capital Management. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Prior to RA, Rob spent 21 years at the Broad Institute of MIT and Harvard, most recently as the Senior Director of Technology Development and a Principal Investigator. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. Nadim Shohdy is an EIR at RA Capital. from Harvard College and an M.B.A. from Harvard Business School. Jon has a PhD in Biomedical Engineering from the University of Michigan, an MS in Mechanical Engineering from Boston University, and a BS in Physics from the University of Washington. Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. Anurag Kondapalli is a Principal on the Investment Team at RA Capital Management. Peter Kolchinsky | Greenwich Economic Forum Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. Brendans primary responsibility is managing all aspects of the tax function. Michael holds a B.S. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. Erins primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. Sarah began her legal career with Foley, Hoag, & Eliot LLP. Max DeNies is a Senior Associate with the TechAtlas division of RA Capital Management. After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Prior to joining RAVen, Habib spent five years as President and CEO at Acceleron Pharma. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). BioSpace's List Of The Top 5 Biggest VC Vampires In Biotech Phi's primary responsibilities at RA Capital are to support the Operations team by coordinating calendars, events, and company meetings. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Ramin completed his internal medicine residency at Brigham & Womens Hospital in Boston and trained in cardiovascular medicine at UCSF. Ryan Russell is a Fund Accountant at RA Capital Management. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. Prior to external consulting and engineering, he gained experience in Helpdesk Specialist and Systems Administrator roles at Withum and Edelstein and Company, LLP. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. So it's not patents holding back production. Americas +1 212 318 2000. Kaleen Sullivan is a Research Operations Manager at RA Capital Management. Soumya spent time as an EIR at IncTank Ventures, where he worked on multiple company creations. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division. Christina holds a PhD in Neuroscience from the Ichan School of Medicine at Mount Sinai and a BS in Biochemistry from Stockholm University. Not so long ago, his mother and father were not rich. Craig holds a BA in Political Science from Bridgewater State College and a JD from Boston College Law School. Hearing the stories of how patients couldn't afford the . from Yale and practiced as a cardiac anesthesiologist. He researched HIV at Harvard, where he earned his PhD, and then co-founded RA Capital Management, a Boston-based life-sciences investment firm focused on funding and creating companies developing new medicines. Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Bens primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Most recently, Brian served as Analyst, Biotech/Pharma/Specialty Pharma at Tamarack Capital Management. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. As Head of Vaccines, he is leading the RA vaccine team to support our evidence-based investment strategy. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. His research investigated chromatin structure and transcription factor binding. In addition, he designs graphics for all internal and external materials. Peter Kolchinsky is a father, scientist, investor, teacher, and author. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. Drinking, Drugs & Smoking Not present. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. BioVentures. Raj holds a BA from Cornell University, where he majored in Chemistry. Peterconducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. She has published over fifty papers in peer reviewed journals. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. Michael held leadership positions at Citigroup Hedge Fund Services in both Fund Accounting and Product Management before joining Centerbridge. He is an Enrolled Agent, admitted to practice before the IRS. In 2013 was awarded a Medical Research Council Clinical Scientist Fellowship. Ana is a Senior Research Assistant, Venture Analytics at RA Capital Management. Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. Candice Galvez is an Executive Assistant at RA Capital Management. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. Shannon's primary responsibilities are to manage the front desk and office facilities. Kathryns primary responsibility at RA is to invest in companies developing solutions that address climate change and environmental sustainability. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. Lorena's primary responsibility is to oversee all accounting related activities for the firm. Jaimie holds a BA in Biology Boston College, with Minors in Medical Humanities and Sociology, and a Master of Public Health from Boston University School of Public Health. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Jesse also held research leadership roles at Moderna Therapeutics and Millennium Pharmaceuticals, where he was responsible for developing novel platforms and leading discovery programs. Before joining Rubius, Mark spent a decade launching, building or advising a portfolio of early-stage venture backed life-sciences companies, including Visterra, Living proof, Kala Pharmaceuticals, and Homology Medicines. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Tom has a BA in Business Administration from St. Anselm College and earned both his Chartered Financial Analyst and Chartered Alternative Investment Analyst designations. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. Ed has 30 years of experience in preclinical and clinical drug development, and in regulatory affairs for pharmaceutical and biotechnology companies. Matt has a BA in Biology with minors in Mathematics and Physics from Ithaca College, a Master of Science in Bioinformatics from Northeastern University, and a PhD in Molecular Biology with a specialization in quantitative biology from Brandeis University. Joels first role in Biotech was as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. Sadik and his teams have contributed to the successful BLA and MAA applications for three of the commercially available CAR-T therapies: Kymriah, Yescarta, and Tecartus. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Sams primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Previously, Shan Shan covered Orphan Heme, Orphan GOF, Vaccines, and various Gene Therapies as a Senior Associate. He is a co-author on over 140 publications and is a co-inventor on 40 issued U.S. patents. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Christina is a Senior Science Writer at RA Capital Management. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche.

David Corbett Obituary, 10 Major Signs Of The Day Of Judgement In Islam, Buffalo Restaurants In The 1960s, Articles P